{"title":"Harnessing artificial intelligence: Revolutionizing clinical care for Parkinson's disease.","authors":"William J Marks","doi":"10.1177/1877718X261436962","DOIUrl":"10.1177/1877718X261436962","url":null,"abstract":"<p><p>As the use of artificial intelligence (AI) in healthcare becomes more pervasive, its application in the clinical care for those with Parkinson's disease (PD) presents exciting opportunities to improve the timeliness and accuracy of diagnosis and to optimize treatment. Perhaps more than many other neurological conditions, PD lends itself to the creation of rich data from which AI can surface actionable insights that hold the potential to revolutionize PD care in a personalized manner. For direct clinical care, AI has the potential to contribute to initial diagnosis, disease subtyping, symptom identification and severity assessment, progression monitoring, and treatment management. With patients and clinicians informing AI and contributing to its methods of deployment, an enormous opportunity exists to open up access to expert-level care to many more people.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"76-80"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147513037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stem cell treatments and Parkinson's disease: Science and misconceptions.","authors":"Athena Stamper, Harry Bulstrode, Roger A Barker","doi":"10.1177/1877718X261434672","DOIUrl":"10.1177/1877718X261434672","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a common neurodegenerative disorder associated with the accumulation of alpha-synuclein in Lewy bodies and Lewy neurites, as well as cell loss, including ventral midbrain dopaminergic (vmDA) neurons in the substantia nigra. This degeneration is responsible for some of the characteristic motor features of PD, which, in the early stages of the disease, can be successfully treated pharmacologically. However, in later stages of the disease, the efficacy of these drugs declines, and they can cause side effects. Dopamine cell therapy, which involves replacing lost vmDA neurons by implanting new exogenous ones, is a promising alternative. While research on dopamine cell therapies has made substantial progress over the last few decades, from early foetal transplants to stem cell-derived transplants currently in clinical trials, it is also susceptible to potential misconceptions. This review summarises the past, present, and future of this therapeutic strategy whilst also discussing these potential misconceptions. In doing so, the status of dopamine cell therapy for PD will be critically summarised.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"5-16"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jessica E Huber, Kevin Renz Ambrocio, Georgia A Malandraki
{"title":"Technology to remotely capture key elements of swallowing and speech: State of the science in Parkinson's disease.","authors":"Jessica E Huber, Kevin Renz Ambrocio, Georgia A Malandraki","doi":"10.1177/1877718X261470565","DOIUrl":"10.1177/1877718X261470565","url":null,"abstract":"<p><p>Swallowing and speech impairments are common in Parkinson's disease (PD) and can significantly affect health and quality of life. Traditional methods for assessing and managing these functions rely on in-person visits and large, expensive equipment, which are inaccessible to many patients. Recent advances in health technologies offer opportunities for remote monitoring and assessment, enabling early detection, personalized intervention, and longitudinal tracking of swallowing and speech deficits in PD. This review synthesizes evidence on current and emerging technologies designed to remotely capture key elements of swallowing and speech in patients with PD. We present studies that develop and use wearable uni- and multi-modal sensor-based approaches, biofeedback devices, acoustic analysis through smartphones, and haptic cueing aimed at improving aspects of swallowing and speech. Additionally, we examine the integration of artificial intelligence for automated signal processing and predictive modeling, emphasizing validation studies and clinical feasibility. Challenges related to usability, data quality, adherence, data security, and standardization are discussed alongside opportunities for telehealth-driven care models. By identifying technological innovations and evidence gaps, this review provides a roadmap for future research and clinical implementation of remote swallowing and speech assessment in PD. These advancements have the potential to transform care, reduce healthcare burden, and improve patient outcomes through scalable, non-invasive, and patient-centered solutions for the management of dysphagia and dysarthria in PD.Plain language summary titleTechnology to remotely measure important parts of swallowing and speech: The current scientific understanding in Parkinson's disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"64-75"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dietary supplements for Parkinson's disease: State of the science.","authors":"Aakash Prasad, Marshal Spenser Shuler, Richelle Flanagan, Viswas Dayal, Fiona E Lithander","doi":"10.1177/1877718X261446386","DOIUrl":"10.1177/1877718X261446386","url":null,"abstract":"<p><p>Parkinson's disease (PD) is the fastest growing neurological condition worldwide with its prevalence set to double by 2050. With no cure in sight, management has turned to lifestyle modification, in particular to diet and exercise. The disease-modifying potential of dietary approaches has been of recent interest, particularly given emerging links between diet and reductions in systemic inflammation, oxidative stress, and alterations in the gut microbiome composition, all of which may modulate neurodegeneration. This review summarises the current 'state of the science' of dietary supplements in modifying disease progression through a lens of the pathophysiological hallmarks of PD. Biomarkers and clinical outcomes that serve as proxy measurements for disease modification are examined, whilst looking ahead at which dietary supplements show the most promise and should be the focus of future research.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"50-63"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147930651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eli Pollard, Leonidas Stefanis, Lorraine V Kalia, Bastiaan R Bloem
{"title":"Proceedings of the 7th world Parkinson congress.","authors":"Eli Pollard, Leonidas Stefanis, Lorraine V Kalia, Bastiaan R Bloem","doi":"10.1177/1877718X261496547","DOIUrl":"https://doi.org/10.1177/1877718X261496547","url":null,"abstract":"","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"16 3_suppl","pages":"3-4"},"PeriodicalIF":5.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Claudio O Fernández Outón, Phelippe Do Carmo Gonçalves, Irina Fernández, Tiago F Outeiro
{"title":"Alpha-synuclein: The main actor at the first Patagonia Synuclein workshop.","authors":"Claudio O Fernández Outón, Phelippe Do Carmo Gonçalves, Irina Fernández, Tiago F Outeiro","doi":"10.1177/1877718X261494920","DOIUrl":"10.1177/1877718X261494920","url":null,"abstract":"<p><p>The accumulation of aggregated alpha-synuclein (aSyn) in the brain is one of the defining pathological features in Parkinson's Disease, Parkinson's Disease with Dementia, Lewy Body Dementia, and Multiple System Atrophy. For this reason, this group of disorders is collectively known as synucleinopathies. The identification of autosomal dominant mutations in the gene encoding aSyn (<i>SNCA</i>) in hereditary forms of disease further supports a central role for this protein in pathogenesis. The Synuclein Workshop was held for the first time in 2025 and is intended to be organized regularly every 2 years in countries of Latin America. The purpose of this series of workshops is to bring together leading experts in the field of synucleinopathies in a part of the world that is known for a strong tradition in the field, and to enable early career researchers to engage with and learn from other renowned experts, with the overall goal of discussing and advancing research in the field. In 2025, the Synuclein Workshop took place in Villa La Angostura, a city located in the province of Neuquén, Argentina. The meeting, entitled \"The Patagonia Synuclein Workshop 2025\", brought together 100 scientists studying both clinical and biomolecular aspects of synucleinopathies. The meeting covered many of the open questions in the field, in a format that promoted and encouraged open and unbiased discussions between the participants, and underscored the need for additional research that, hopefully, will lead to the development of new diagnostic tools and therapeutic strategies. Here, we provide a summary of the main topics discussed in the meeting, and highlight what is the current knowledge in the field, what we still do not know, and the future directions necessary for achieving the ultimate goal of the community: to offer better options to patients, families, and care-givers.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261494920"},"PeriodicalIF":5.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marie-Louise Zeissler, Kevin McFarthing, Michèle Bartlett, Natasha Fothergill-Misbah, Camille B Carroll, Ríona McArdle
{"title":"Supporting meaningful contributions of people affected by Parkinson's throughout the research process: Key considerations for inclusive patient and public involvement across the globe.","authors":"Marie-Louise Zeissler, Kevin McFarthing, Michèle Bartlett, Natasha Fothergill-Misbah, Camille B Carroll, Ríona McArdle","doi":"10.1177/1877718X261502271","DOIUrl":"10.1177/1877718X261502271","url":null,"abstract":"<p><p>Patient and public involvement (PPI), defined as research undertaken <i>with</i> people affected by a condition as partners rather than participants, is increasingly recognized as a marker of high-quality research and is now encouraged or required by many funders. Research agendas and practices need to reflect the realities of people living with Parkinson's Disease (PD) ensuring research addresses the priorities of those affected.This narrative review examines the role of PPI across the research cycle, including priority setting, commissioning, study design, delivery, dissemination, implementation, and evaluation. We provide guidance and practical examples of how meaningful PPI can be achieved in PD research. The review explains how perspectives of lived experience can improve the relevance, feasibility, accessibility, and highlight its impact on PD research. We discuss practical considerations for embedding meaningful PPI, including project governance structures, dedicated staffing, remuneration, flexibility in conduct, and how to embed the perspectives of under-served PD communities in PPI. Finally, we consider challenges and opportunities for PPI in low- and middle-income countries, where underdiagnosis, stigma, health literacy barriers, and structural inequities require culturally responsive and community-led approaches.Involving people affected by Parkinson's as equal partners in research has the potential to improve individual studies and to reshape the wider PD research agenda to be more inclusive, representative, and responsive to the priorities of those most affected.To realise this potential, we must make a collective commitment to treat PPI as a requirement, provide funding and infrastructure support for implementation, and share experiences.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261502271"},"PeriodicalIF":5.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13713908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rachel Cullinan, Alison J Yarnall, Glenn Stebbins, John-Paul Taylor, David J Burn, Louise M Allan, Sarah J Richardson, Andrew Teodorczuk, Rachael A Lawson
{"title":"Qualitative analysis of staff views on caring for inpatients with delirium and Parkinson's disease: Challenges, tensions and team working.","authors":"Rachel Cullinan, Alison J Yarnall, Glenn Stebbins, John-Paul Taylor, David J Burn, Louise M Allan, Sarah J Richardson, Andrew Teodorczuk, Rachael A Lawson","doi":"10.1177/1877718X261499241","DOIUrl":"https://doi.org/10.1177/1877718X261499241","url":null,"abstract":"<p><p>ObjectivesPeople with Parkinson's disease (PD) are at increased risk of delirium. Documentation of delirium is poor, with challenges in making a diagnosis due to overlapping symptoms. This study interviewed healthcare workers about their experiences of caring for inpatients with PD and delirium to explore their perspectives.DesignA qualitative study with semi-structured interviews and thematic analysis.ParticipantsTwelve healthcare staff, comprising five doctors and seven nurses.ResultsFour themes emerged: environmental pressures, relationship tensions, challenges and team working. We divided findings into those relevant to all inpatients with delirium and those specific to patients with PD and delirium. Environment pressures negatively impacted on all patients with delirium, and empathy was expressed for all carers/relatives. Staff anxiety was higher caring for patients with PD and relationship tensions occurred with juxtaposition of staff delirium expertise and patient/carer lived experience of PD. PD specific challenges were PD medications and a reciprocal relationship between diagnostic overshadowing and identifying the cause of delirium. Roles of ward nursing team to identify acute changes and doctors to identify and diagnose delirium in all patients was clearly defined.ConclusionsThis study identified knowledge gaps and lack of confidence specific to patients with delirium and PD. We recommend clearer definition of delirium superimposed on PD, with education and training on its complexity, alongside inclusion of expert-by-experience teaching. Future study of patient and carer views will help better understand the relationship tensions and how we can improve patient care and experiences.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261499241"},"PeriodicalIF":5.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13694458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer L McGinley, Michele Callisaya, Belinda Gabbe, Kate Behm, Victor McConvey, Jennifer Jones, Raphael Hau, Mícheál Ó Breasail, Sze-Ee Soh
{"title":"Outcomes of isolated hip fractures in people with Parkinson's disease: An observational cohort study using propensity score methods.","authors":"Jennifer L McGinley, Michele Callisaya, Belinda Gabbe, Kate Behm, Victor McConvey, Jennifer Jones, Raphael Hau, Mícheál Ó Breasail, Sze-Ee Soh","doi":"10.1177/1877718X261499245","DOIUrl":"10.1177/1877718X261499245","url":null,"abstract":"<p><p>BackgroundPeople with Parkinson's disease (PwP) have a high risk of hip fracture and the outcomes of PwP in Australia with hip fractures are unknown.ObjectiveTo describe the characteristics of PwP who present with a hip fracture and to examine the association between Parkinson's with acute hospital outcomes, mortality and discharge destination.MethodsWe conducted a cohort study of individuals with an isolated proximal femur fracture using the Victorian Orthopaedic Trauma Outcomes Registry (Australia) from 2016 to 2022. Demographic characteristics, comorbidities, fracture types, acute hospital length of stay, discharge destination and 30-day and 12-month mortality data were extracted. Inverse-probability weighting with estimated propensity scores determined the association of Parkinson's with outcomes, using a logistic regression model that included covariates and injury characteristics.ResultsOf 5,553 patients, 208 (4%) had PD, with a mean age of 79.9 years (SD 12.9). After propensity score adjustment, there was no association between Parkinson's and ICU admission (OR 1.89; 95% CI 0.67, 5.34), acute length of stay (adjusted median 6.9 vs 7.7) and 12-month mortality rates (OR 1.25; 95% CI 0.85, 1.82). PwP were more likely to be discharged to rehabilitation than home (RR 2.04; 95% CI 1.12, 3.74).ConclusionsWe did not observe a statistically significant difference in acute hospital outcomes between the two cohorts, including length of stay. This is encouraging as avoiding prolonged hospitalisation reduces health care costs and risk of hospital-related harms. However, these findings may reflect limited statistical power and differences between groups cannot be excluded. Further research is also indicated to explore post-care discharge pathways and longer-term functional outcomes of this group.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261499245"},"PeriodicalIF":5.9,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149245045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Teamwork in Parkinson's care: Building multidisciplinary models worldwide.","authors":"Marieke Cj Dekker, Kanyawat Sanyawut, Lim Thien Thien, Hoe Wei Leng, Onanong Phokaewvarangkul","doi":"10.1177/1877718X261499242","DOIUrl":"10.1177/1877718X261499242","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a complex, progressive neurodegenerative disorder requiring comprehensive, long-term management. PD affects millions of people globally and presents with motor and non-motor symptoms that progressively impair function and quality of life. While pharmacological therapy remains effective, optimal care extends beyond medication management. Traditional care models for PD often rely heavily on doctors and primarily target motor symptoms and motor complications, with less attention to non-motor symptoms, many of which remain under-recognized. This imbalance contributes to fragmented care and unmet patient needs. These challenges highlight the need for a multidisciplinary care team to address the full spectrum of patient needs. Therefore, integrating a multidisciplinary approach is essential for comprehensive PD management. This manuscript proposes a scalable, multidisciplinary care team model designed to optimise clinical outcomes, enhance quality of life, and remain adaptable across diverse healthcare systems worldwide. It addresses global challenges associated with MDT implementation and outlines potential future solutions. The manuscript also highlights stakeholder engagement in Community Engagement and Involvement (CEI), including initiatives in Tanzania and Thailand to raise community awareness. In particular, the \"CheckPD\" project and integrated \"eat, move, sleep\" lifestyle interventions promote lifestyle-based strategies for PD prevention and improved long-term management of PD. Overall, the model emphasises coordinated, patient-centred care that integrates medical, rehabilitative, psychological, and social support services.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261499242"},"PeriodicalIF":5.9,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13691001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}